Danaher Corp /De/ (DHR) stock price, news and key stats
Price
Last close as of Sep 16, 2026. Delayed data; not a live quote.
- Previous close
- $209.36
- Open
- $209.67
- Day range
- $206.68 – $211.98
- Volume
- 3.6M
About Danaher Corp /De/
Danaher Corporation is a diversified healthcare and life sciences company, primarily exposed to demand in bioprocessing and life sciences markets.
Latest DHR news
- Danaher (DHR) Seen Deftly Navigating AI IntegrationYahoo Finance · Sep 3, 2026
Danaher Corporation (DHR) is being recognized for its strategic approach to integrating artificial intelligence (AI) across its diverse portfolio of life sciences and diagnostics businesses. Analysts highlight the company's ability to leverage AI technology to enhance operational efficiency, improve product offerings, and drive innovation. This integration is expected to bolster Danaher's competitive edge in the rapidly evolving healthcare and scientific research sectors. Market analysts are optimistic about the potential for AI to streamline processes and reduce costs, which could lead to increased profitability for Danaher. The company's investments in AI-driven solutions are seen as a proactive measure to meet the growing demand for advanced healthcare technologies. As the market increasingly values companies that can adapt to technological advancements, Danaher's focus on AI integration may attract investor interest, positively impacting its stock performance in the coming quarters.
- Aggregate Retention Filter Underlayers Market Outlook to 2035Market Outlook · Aug 30, 2026
The Aggregate Retention Filter Underlayers market is poised for significant growth, driven primarily by the increasing demand for stringent drainage solutions in electronics and semiconductor cleanroom infrastructures. With an estimated annual growth rate of 4-6% projected through 2035, the market is expected to see substantial expansion as industries prioritize high-quality filtration systems to meet regulatory standards and operational efficiency. The broader filtration market, which surpassed USD 53.5 billion in 2025, is also on an upward trajectory, with a compound annual growth rate (CAGR) of 4.2% anticipated until 2035. This growth is largely attributed to heightened investments in drug manufacturing and biotechnology research, both of which require ultra-pure environments that can only be achieved through advanced filtration technologies. As the demand for premium-grade underlayers, certified for high performance, continues to rise, manufacturers are likely to focus on innovation and quality to capture market share. Market analysts suggest that the Aggregate Retention Filter Underlayers segment will benefit from the overall expansion of the filtration market, particularly as sectors such as pharmaceuticals and electronics increasingly rely on advanced filtration solutions. This trend could lead to increased competition among manufacturers, driving technological advancements and potentially lowering costs for end-users over time. As the market evolves, stakeholders will need to stay attuned to regulatory changes and technological advancements that could shape future demand dynamics.
- Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?Yahoo Finance · Aug 23, 2026
Investors in the healthcare sector are currently weighing the merits of two prominent companies: Danaher Corporation and Intuitive Surgical. Danaher, a diversified conglomerate known for its life sciences and diagnostics segments, is emerging from a period of slower growth, primarily due to pandemic-related disruptions. As the global healthcare landscape stabilizes, Danaher is poised to benefit from increased demand for its products and services, particularly in diagnostics and bioprocessing. Analysts suggest that the company's robust portfolio and operational efficiencies could lead to a strong recovery trajectory, making it an attractive option for conservative investors seeking stability. In contrast, Intuitive Surgical, the pioneer of robotic-assisted surgery with its da Vinci Surgical System, is focused on innovation and expanding its market share. The company has consistently invested in research and development to enhance its surgical systems and expand their applications across various medical fields. As healthcare providers increasingly adopt robotic-assisted procedures, Intuitive Surgical is well-positioned for long-term growth. However, the company faces challenges, including rising competition and regulatory scrutiny, which could impact its market performance. The decision between investing in Danaher or Intuitive Surgical ultimately hinges on an investor's risk tolerance and growth expectations. Danaher offers a recovery play with potential for steady returns as it rebounds from recent setbacks, while Intuitive Surgical presents a more aggressive growth opportunity driven by innovation. As both companies navigate the evolving healthcare landscape, their respective strategies will be critical in determining their long-term success and appeal to investors.
- Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?Yahoo Finance · Aug 23, 2026
Investors are weighing the recovery trajectories of Danaher Corporation and Medtronic as the healthcare sector shows signs of improvement. Danaher (NYSE:DHR) is experiencing a resurgence driven by enhanced demand in its life sciences segment, particularly as respiratory challenges diminish and bioprocessing markets rebound. Analysts are optimistic about Danaher's growth potential, forecasting that revenue could accelerate significantly by 2027, making it a compelling buy for investors looking for long-term gains. In contrast, Medtronic (NYSE:MDT) faces a more complex recovery narrative. The company has been grappling with operational challenges and regulatory scrutiny, which have hindered its ability to capitalize on the broader market recovery. While Medtronic is implementing strategic changes to enhance its product offerings and streamline operations, the pace of its recovery remains uncertain. Investors are advised to consider the differing recovery paths of these two companies, as Danaher's upward momentum may present a more attractive investment opportunity compared to Medtronic's ongoing struggles. As the healthcare market continues to evolve, the performance of these companies will likely influence broader sector trends. Investors should remain vigilant, as the contrasting recovery stories of Danaher and Medtronic could shape investment strategies in the healthcare space moving forward.
Index membership
- S&P 500 · Health Care
Related Health Care stocks
Chart, AI research and agents for DHR
Open DHR in Watchgar for the live chart, AI-graded news, insider and institutional flow, and automated trading agents. Free to start, no card required.
Open DHR in Watchgar